OpenAI acquires Orchestra Bio to add drug development coordination to Rosalind

AIOpenAI has acquired Orchestra Bio, a platform whose AI agents monitor studies and timelines across departments and contractors in drug development. The deal adds Orchestra's team and technology to OpenAI's Rosalind life sciences tools, which the company says aims to help scientists turn discoveries into treatments sooner. The post notes that drug development averages 10 to 15 years from target to US approval, and that Anthropic bought Coefficient Bio for roughly $400M in stock in April.

AIAndrew Curran says drug discovery, new disease cures, and advances in pharma and biomedicine are the only viable ways to turn public sentiment around on AI, with direct dividends or shares also being discussed. He predicts the big push will start in 2027. The post cites OpenAI's acquisition of Orchestra Bio, a platform for biopharma drug development coordination.

AIOpenAI has acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development. OpenAI says it will build on Rosalind, its AI models and tools for life sciences research, to streamline those operations and help new treatments reach patients sooner.